drugset / Trial / NCT01715805

Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)

NCT01715805

Phase 3 Completed 1022 enrolled Forest Laboratories Gedeon Richter Ltd. · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

The objective of this study is to evaluate the efficacy, safety and tolerability of cariprazine as an adjunctive treatment to antidepressant therapy (ADT) in patients with MDD

Timeline

Start
2012-11-15
Primary completion
2016-06-24
Completion
2016-06-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Cariprazine Small molecule 1.5 mg Oral
Subject Cariprazine Small molecule 4.5 mg Oral
Background Bupropion Small molecule
Background Citalopram Small molecule
Background Desvenlafaxine Other / unclassified
Background Duloxetine Small molecule
Background Escitalopram Small molecule
Background Fluoxetine Small molecule
Background Paroxetine Small molecule
Background Sertraline Small molecule
Background Venlafaxine Small molecule
Background Vilazodone Small molecule